The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Gliomas are the most common malignant primary brain tumors, of which glioblastoma is the
most malignant form (WHO grade IV), and notorious for treatment resistance. Over the last …

Summary N 7-methylguanosine (m 7 G) modification, routinely occurring at mRNA 5′ cap
or within tRNAs/rRNAs, also exists internally in messenger RNAs (mRNAs). Although m 7 G …

Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with
histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune …

Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …

Despite substantial advances in targeting mutant KRAS, tumor resistance to KRAS inhibitors
(KRASi) remains a major barrier to progress. Here, we report proteostasis reprogramming as …

The Bromo-and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles
in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Effective treatment for glioblastoma (GBM) is limited by the presence of the blood–brain
barrier (BBB) and rapid resistance to single agent therapies. To address these issues, we …

Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant
acetylation levels have been linked to the development of several diseases. Acetyl-lysine …